Our first guarantee supports the Hologic Global Access Initiative, a partnership between Hologic, Inc., the Clinton Health Access Initiative and MedAccess, to mitigate the burden of viral diseases, including HIV, Hepatitis B, Hepatitis C and human papillomavirus. This initiative provides greater access to molecular testing on Hologic’s Panther® testing platform. Our second partnership, with BASF SE and the Bill & Melinda Gates Foundation, supports access to BASF’s next-generation Interceptor® G2 insecticide-treated bed nets.
The agreement with Hologic supported the scale up of the use of Panther® in seven countries in sub-Saharan Africa during 2019. More than one million tests were procured by these countries, contributing to improved clinical outcomes for an estimated 182,000 patients. With an all-inclusive ceiling price of $12 per patient test, a 30 per cent price reduction has been achieved compared to other suppliers. This reduction saved procurers approximately $7 million in 2019.
Our guarantee for BASF’s Interceptor® G2 insecticide-treated bed nets was announced in October 2019. By the end of the year, 8.1 million nets had been ordered by five countries, with 3.2 million delivered to Burkina Faso and Rwanda. The negotiated price reduction with BASF saved at least $5 million for global health procurers last year.
Welcoming the report, CEO Michael Anderson said:
Our finances in 2019
MedAccess delivered a strong financial performance in 2019 and we maintain a robust balance sheet. As a social finance company, any surpluses are reinvested in the business and used to support future guarantees.
Our ability to support a larger guarantee portfolio and a wider scope of activities has been augmented by CDC Group plc’s contribution of $100 million of additional capital in 2019. This contribution was envisaged when MedAccess was formed and it underscores our parent company’s confidence in our work.
Financial sustainability is a critical component of our business model. By sustaining ourselves over the long-term, we are positioned to continue to deliver development impact.
Evans Mburu, our implementation executive, knows first-hand TB’s devastating impact. Watch Evans share his story about taking TB treatment.
The longer a mosquito population is exposed to a single class of insecticides, the longer it has had to build resistance. Dr. Tom McLean from IVCC explores three insecticide tools at market and in development to battle resistance.
New malaria technologies are tackling the problem of insecticide resistance in mosquitos. Dr. Tom McLean from IVCC discusses how to get these new tools to the people who need them.
Through the Global Access Initiative, we are helping to increase access viral load testing through the Panther platform. Ahead of World AIDS Day 2020, two laboratory technicians in Kenya and Zambia told us how Panther is helping them to better serve patients.